Interferon beta for primary progressive multiple sclerosis

Cochrane Database of Systematic Reviews

Volumn , Issue 3, 2007, Pages

  Rojas, Juan I ^a   Romano, M ^b   Ciapponi, A ^b   Patrucco, L ^b   Cristiano, E ^b  

^a HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON;

CLINICAL PROTOCOL; CLINICAL RESEARCH; COCHRANE LIBRARY; EMBASE; HUMAN; IMMUNOTHERAPY; MEDLINE; MULTIPLE SCLEROSIS; OUTCOMES RESEARCH; REVIEW;

EID: 44949118654     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD006643     Document Type: Review

References (23)

1. Cohen 2002 Cohen JA, Cutter GR, Fisher JS, Goodman AD, Heindenreich FR, Kooijmans MF, et.al. Benefit of interferon-beta-1a on MSFC progression in secondary progressive MS. Neurology 2002;59:679-87.
2. Confavreux 2006 Confavreux C, Vukusic S. Natural history of multiple sclerosis: a unifying concept. Brain 2006;129:606-16.
3. Egger 1997 Egger M, Davey Smith G, Schneider M, Minder C. Bias in Meta-analysis detected by a simple, graphicall test. British Medical Journal 1997;315(7109):629-34.
4. ESG 1998 Kappos L, Polman C, Pozzilli C, Thompson A, Dahlke F, et.al. Placebo-controlled multicentre randomised trial of intreferon beta-1b in tratment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS. The Lancet 1998;352(9139):1491-7.
5. Higgins 2005 Higgins JPT, Green S, editor. Cochrane Handbook for Systematic Reviews of Interventions 4.2.6. [Updated May 2005]. The Cochrane Library. Vol. Issue 3,, Chichester, UK: John Wiley & Sons, Ltd, 2005.
6. IFNB MSSG 1993 The IFNB Multiple Sclerosis Group. Interferon beta 1-b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655-61.
7. Jadad 1996 Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et. al. Assessing the quality of reportes of randomized clinical trials: is blinding necessary. Controlled Clinical Trials 1996;17:1-12.
8. Kremenchutzky 2006 Kremenchutzky M, Rice GP, Baskerville J, Wingerchuk DM, Ebers GC. The natural history of multiple sclerosis: a geographically based study 9: observations on the progressive phase of the disease. Brain 2006;129:584-94.
9. Kurtzke 1983 Kurtzke JF. Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33(11):1444-52.
10. Leary 2003 Leary SM, Thompson AJ. Interferon beta-1a in primary progressive multiple sclerosis. Journal of the neurological sciences 2003;206(2):215-6.
11. Lublin 1996 Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. Natinal Multiple Sclerosis Society (USA) Advisory Committe on Cinical Tials of new agents in Multiple Sclerosis. Neurology 1996;46(4):907-11.
12. McDonald 2001 McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et. al. Recommended disgnostic criteria formultiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Annals of Neurology 2001;50:121-7.
13. MSCRG 1996 Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, et. al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Annals of neurology 1996;39(3):285-94.
14. NASG 2004 Panitch H, Miller A, Paty D, Weinshenker B, North American Study Group on Interferon beta-1b in Secondary Progressive MS. Interferon beta-1b in Secondary Progressive MS: Results from a 3 year controlled study. Neurology 2004;63:1788-95.
15. Poser 1983 Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Annals of Neurology 1983;13(3):227-31.
16. PRISMS 1998 Prevention of Relapses, Disability by Interferon beta-1a subcutaneously in Multiple Sclerosis. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing-remiting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by interferon-beta1a Subcutaneously in Multiple Sclerosis) Study Group. The Lancet 1998;352(9139):1498-504.
17. Rice 2001 Rice GP, Incorvaia B, Munari L, Ebers G, Polman C, D'Amico R, Filippini G. Interferon in relapsing-remitting multiple sclerosis. Cochrane Database of Systematic Reviews 2001, Issue 4.Art. No.: CD002002. DOI:10.1002/14651858.CD002002.
18. SPECTRIMS 2001 Secondary Progressive Efficacy Clinical Trials of Recombinant Interferon-beta-1a in MS (SPECTRIMS) Study Goup. Randomized Controlled Trial of Interferon-beta1-a in scondary pogressive MS. Clinical results. Neurology 2001;56:1496-504.
19. Stevenson 1999 Stevenson VL, Miller DH, Rovaris M, Barkhof F, Brochet B, Dousset V, et. al. Primary and transitional MS: a clinical and MRI cross-sectional study. Neurology 1999;52(4):839-45.
20. Thompson 1997 Thompson AJ, Polman CH, Miller DH, McDonald WI, Brochet B, Filippi M, et. al. Primary progressive multiple sclerosis. Brain 1997;120(6):1085-1096.
21. Thompson 2000 Thompson AJ, Montalban X, Barkhof F, Brochet B, Filippi M, Miller DH, et. al. Diagnostic criteria for PPMS: a position paper. Annals of neurology 2000;47:831-5.
22. van Lambalgen 1986 van Lambalgen R, Sanders EA, D'Amaro J. Sex distribution, age of onset and HLA profiles in two types of multiple sclerosis. A role for sex hormones and microbial infections in the development of autoimmunity?. Journal of neurological sciences 1986;76:13-21.
23. Vickrey 1995 Vickrey BG, Hays RD, Harooni R, Myers LW, Ellison GW. A health-related quality of life measure for multiple sclerosis. Quality of life research 1995;4:187-206.